- Simulations Plus's total return overperformed the Dow average for my 67-month test period by 308.05%, which is great, and the recent dip is a buying opportunity.
- Simulations Plus's three-year past CAGR of 18.5% is well above average and will give you great growth with the increasing need to test new drugs faster than before.
- Simulations Plus's recent earnings were fair, just beating on the top and missing bottom-line but showing growth YOY with great innovative software products growing strongly.
- The service business had a revenue dip which will carry into the fourth quarter but is estimated to start growing again at the beginning of 2022.
For further details see:
Simulations Plus: Growth Speculation, Buy The Dip In This Drug Testing Company